Hyperphosphatemia Clinical Trial
Official title:
Velphoro and Impact on the Oral Cavity and Gut Microbiome
This pilot study will be carried out to determine if the regular intake of iron-based Velphoro® by hyperphosphatemia patients influences the microbiome in the oral cavity and/or the gut.
The aim of this study is to investigate potential changes in the microbiome of the oral cavity and/or gut in patients with hyperphosphatemia following Velphoro® intake for one month. The principal intention of this study is to assess consequences of Velphoro® medication beyond phosphate control. Adherence to the drug might be compromised by e.g. staining of teeth and biofilm after chewing the product more than recommended. Most likely this is a cosmetic problem only and easy to solve by optimizing oral hygiene. The increased level of iron may have an effect on the gut microbiome which could lead to mild diarrhoea. However, the present study will assess, whether the microbiome both oral and gut changes significantly due to some iron bio-availability, although this is expected to be low with sucroferric oxyhydroxide. The ultimate goal is to improve patient adherence to the drug and to resolve potential safety concerns. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT02237534 -
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
|
Phase 4 | |
| Completed |
NCT01187628 -
Long-term Study in Chronic Kidney Disease (Extension From Study 14817)
|
Phase 3 | |
| Completed |
NCT01252771 -
Phosphate Kinetic Modeling 2
|
Phase 4 | |
| Unknown status |
NCT01245517 -
The Influence of Dietary Phosphorus Education Program on Nutritional Status and Serum Phosphate Level Among Hemodialysis Patient
|
N/A | |
| Completed |
NCT00506441 -
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
|
Phase 3 | |
| Recruiting |
NCT04440696 -
To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder
|
Phase 1/Phase 2 | |
| Completed |
NCT01976572 -
Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01742585 -
A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
|
Phase 3 | |
| Completed |
NCT01191255 -
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
|
Phase 3 | |
| Completed |
NCT01003223 -
Phosphate Kinetic Modeling
|
N/A | |
| Completed |
NCT00505037 -
A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
|
Phase 2 | |
| Completed |
NCT00508885 -
The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT04551300 -
A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients
|
Phase 2 | |
| Completed |
NCT01955876 -
Fosrenol Post-marketing Surveillance in Japan
|
N/A | |
| Completed |
NCT04579315 -
Long-term Effects of the New Nordic Renal Diet in Patients With Moderate Chronic Kidney Disease
|
N/A | |
| Completed |
NCT03861247 -
Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients
|
Phase 3 | |
| Terminated |
NCT01725113 -
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
|
Phase 4 | |
| Recruiting |
NCT01238588 -
The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan
|
N/A | |
| Completed |
NCT00542815 -
A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
|
Phase 3 | |
| Completed |
NCT04549597 -
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
|
Phase 4 |